In a report issued on June 30, Joel Beatty from Robert W. Baird reiterated a Buy rating on Blueprint Medicines (BPMC – Research Report), with a price target of $96.00. The company’s shares closed last Friday at $49.93, close to its 52-week low of $43.46.
According to TipRanks.com, Beatty is a 3-star analyst with an average return of 1.9% and a 49.4% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Arrowhead Pharmaceuticals, and BioMarin Pharmaceutical.
Currently, the analyst consensus on Blueprint Medicines is a Moderate Buy with an average price target of $79.78, a 59.4% upside from current levels. In a report issued on June 30, Stifel Nicolaus also maintained a Buy rating on the stock with a $90.00 price target.
The company has a one-year high of $117.86 and a one-year low of $43.46. Currently, Blueprint Medicines has an average volume of 791.7K.
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BPMC in relation to earlier this year. Most recently, in May 2022, Nicholas Lydon, a Director at BPMC bought 10,909 shares for a total of $213,053.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
Read More on BPMC: